Authors
Latest:
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical ProgressionIn the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
Latest:
Efficacy and Safety of Zolbetuximab in Gastric CancerZolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
Latest:
Digital Pathology and AI May be ‘Valuable Tools’ in Prostate CancerArtificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Latest:
Which Larynx-Preservation Strategy Would Be Best for a Patient With Resectable, Locally Advanced, Hypopharynx Squamous Cell Carcinoma?A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.
Latest:
Cancer Pain and Opioid Use DisorderInvestigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
Latest:
Kohei Shitara, MD, Discusses Immunotherapy in Gastric Cancer at 2022 IGCCKohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.
Latest:
Future Perspectives in HER2+ mBCThe panel closes their discussion by musing on the future of HER2 mBC treatments.
Latest:
Life After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple MyelomaLife After CAR T: Patient and Clinical Perspectives on the Promise of CAR T in Multiple Myeloma
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and PhysiciansPractical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.
Latest:
Consideration of Long-Term Physical Health Effects From Breast Cancer Therapies“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
3 Things You Should Know About Hemolytic AnemiasHemolytic anemias are a collection of rare but severe diseases including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Latest:
Integrative Oncology in Young Women With Breast CancerYancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Latest:
Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCLAn expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.
Latest:
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head MassRohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Latest:
BMS-986393 Appears Effective, Safe in Relapsed/Refractory Multiple MyelomaGPRC5D may be a promising therapeutic pathway in the treatment of those with relapsed/refractory multiple myeloma, says Susan Bal, MD.
Latest:
Improving NSCLC Surgery Recovery After Climate Disaster ExposureThe “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Latest:
Ensuring Safe Bispecific Antibody Use in Lymphoma at Community PracticesHarmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Latest:
KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Latest:
Daniel M. Geynisman, MD, on Optimal Therapy Selection in RCCAt 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.
Latest:
Key Takeaways and Future in Advanced Gastric Cancer TreatmentPanelists discuss how future analyses in advanced gastric cancer should assess long-term survival, real-world outcomes, biomarkers for response, resistance mechanisms, and patient selection for nivolumab plus chemotherapy. Evaluating these factors will optimize treatment strategies and confirm its role across diverse populations.
Latest:
Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer SymposiumThe expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.
Latest:
Future Therapies for ALK+ Metastatic NSCLCDr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
